Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab plus paclitaxel and platinum chemotherapy for first-line treatment of NSCLC brain metastases
ChiCTR2500110285Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Sichuan Cancer Hospital. Primary endpoints: progression-free survival and intracranial progression-free survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2500110285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110285.